1
|
Pan Y, Deng L, Wang H, He K, Xia Q. Histidine-rich glycoprotein (HRGP): Pleiotropic and paradoxical effects on macrophage, tumor microenvironment, angiogenesis, and other physiological and pathological processes. Genes Dis 2022; 9:381-392. [PMID: 35224154 PMCID: PMC8843877 DOI: 10.1016/j.gendis.2020.07.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 07/15/2020] [Accepted: 07/31/2020] [Indexed: 12/14/2022] Open
Abstract
Histidine-rich glycoprotein (HRGP) is a relatively less known glycoprotein, but it is abundant in plasma with a multidomain structure, which allows it to interact with many ligands and regulate various biological processes. HRGP ligands includes heme, Zn2+, thrombospondin, plasmin/plasminogen, heparin/heparan sulfate, fibrinogen, tropomyosin, IgG, FcγR, C1q. In many conditions, the histidine-rich region of HRGP strengthens ligand binding following interaction with Zn2+ or exposure to low pH, such as sites of tissue injury or tumor growth. The multidomain structure and diverse ligand binding attributes of HRGP indicates that it can act as an extracellular adaptor protein, connecting with different ligands, especially on cell surfaces. Also, HRGP can selectively target IgG, which blocks the production of soluble immune complexes. The most common cell surface ligand of HRGP is heparan sulfate proteoglycan, and the interaction is also potentiated by elevated Zn2+ concentration and low pH. Recent reports have shown that HRGP can modulate macrophage polarization and possibly regulate other physiological processes such as angiogenesis, anti-tumor immune response, fibrinolysis and coagulation, soluble immune complex clearance and phagocytosis of apoptotic/necrosis cells. In addition, it has also been reported that HRGP has antibacterial and anti-HIV infection effects and may be used as a novel clinical biomarker accordingly. This review outlines the molecular, structural and biological properties of HRGP as well as presenting an update on the function of HRGP in various physiological processes.
Collapse
|
2
|
Wake H. [Role of histidine-rich glycoprotein as anti-DAMPs and therapeutic effects on DAMPs-related diseases]. Nihon Yakurigaku Zasshi 2022; 157:426-428. [PMID: 36328553 DOI: 10.1254/fpj.22074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Histidine-rich glycoprotein (HRG) is a plasma glycoprotein produced mainly in the liver. We have shown that HRG replacement therapy has a marked therapeutic effect on sepsis, in which high mobility group box 1 (HMGB1), one of the representative damage-associated molecular patterns (DAMPs), is known to play an important role in the disease progression. The mechanisms of action are diverse, including inhibition of immune thrombus formation and inhibition of ROS production. In addition, HRG has been shown to neutralize the toxicity of heme, a type of DAMPs, and neutralize the activity of LPS, a type of pathogen-associated molecular patterns (PAMPs), and to inhibit the translocation of HMGB1 from the nucleus of vascular endothelial cells to the extracellular space. Since DAMPs/PAMPs are known to play a central role in the pathogenesis of not only sepsis but also many inflammatory diseases, HRG has wide therapeutic applications and is considered to be a very promising seed for drug discovery.
Collapse
Affiliation(s)
- Hidenori Wake
- Department of Pharmacology, Faculty of Medicine, Kindai University
| |
Collapse
|
3
|
Anti-Angiogenic and Anti-Proliferative Graphene Oxide Nanosheets for Tumor Cell Therapy. Int J Mol Sci 2020; 21:ijms21155571. [PMID: 32759830 PMCID: PMC7432113 DOI: 10.3390/ijms21155571] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Revised: 07/31/2020] [Accepted: 08/01/2020] [Indexed: 02/07/2023] Open
Abstract
Graphene oxide (GO) is a bidimensional novel material that exhibits high biocompatibility and angiogenic properties, mostly related to the intracellular formation of reactive oxygen species (ROS). In this work, we set up an experimental methodology for the fabrication of GO@peptide hybrids by the immobilization, via irreversible physical adsorption, of the Ac-(GHHPH)4-NH2 peptide sequence, known to mimic the anti-angiogenic domain of the histidine-proline-rich glycoprotein (HPRG). The anti-proliferative capability of the graphene-peptide hybrids were tested in vitro by viability assays on prostate cancer cells (PC-3 line), human neuroblastoma (SH-SY5Y), and human retinal endothelial cells (primary HREC). The anti-angiogenic response of the two cellular models of angiogenesis, namely endothelial and prostate cancer cells, was scrutinized by prostaglandin E2 (PGE2) release and wound scratch assays, to correlate the activation of inflammatory response upon the cell treatments with the GO@peptide nanocomposites to the cell migration processes. Results showed that the GO@peptide nanoassemblies not only effectively induced toxicity in the prostate cancer cells, but also strongly blocked the cell migration and inhibited the prostaglandin-mediated inflammatory process both in PC-3 and in HRECs. Moreover, the cytotoxic mechanism and the internalization efficiency of the theranostic nanoplatforms, investigated by mitochondrial ROS production analyses and confocal microscopy imaging, unraveled a dose-dependent manifold mechanism of action performed by the hybrid nanoassemblies against the PC-3 cells, with the detection of the GO-characteristic cell wrapping and mitochondrial perturbation. The obtained results pointed out to the very promising potential of the synthetized graphene-based hybrids for cancer therapy.
Collapse
|
4
|
Wake H, Nishibori M. [Various functions of plasma histidine-rich glycoprotein and its clinical application as the biomarker and therapeutic drug for sepsis]. Nihon Yakurigaku Zasshi 2020; 155:155-158. [PMID: 32378634 DOI: 10.1254/fpj.19150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Histidine-rich glycoprotein (HRG) is a 75 kDa plasma glycoprotein synthesized in liver mainly, which exists at approximately 60-100 μg/ml in human plasma. HRG is known to bind to several ligands and cells, leading to exert coagulation, fibrinolysis, immune and inflammation regulatory activity in septic condition. Thus, decreased plasma HRG level induces the dysregulations of coagulation, fibrinolysis and immune system, resulting in disseminated intravascular coagulation and multiple organ failure. This article focuses on the physiological activity of HRG and the potential of HRG as the biomarker and therapeutic drug for sepsis.
Collapse
Affiliation(s)
- Hidenori Wake
- Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
| | - Masahiro Nishibori
- Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
| |
Collapse
|
5
|
Mattii L, Bianchi F, Falleni A, Frascarelli S, Masini M, Alì G, Chiellini G, Sabbatini ARM. Ultrastructural Localization of Histidine-rich Glycoprotein in Skeletal Muscle Fibers: Colocalization With AMP Deaminase. J Histochem Cytochem 2019; 68:139-148. [PMID: 31880188 DOI: 10.1369/0022155419897573] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Histidine-rich glycoprotein (HRG) is a plasma protein synthesized by the liver. We have given the first evidence of a tissue localization of HRG demonstrating its presence in skeletal muscle, associated with the zinc enzyme AMP deaminase (AMPD1). Moreover, we have shown that muscle cells do not synthesize HRG, but they can internalize it from plasma. We have recently demonstrated by confocal laser scanning microscopy that in human skeletal muscle, HRG is mainly localized in the myofibrils, preferentially at the I-band of the sarcomere, in the sarcoplasm, and in the nuclei. Using transmission electron microscopy and immunogold analysis, we carried out this study on human and rat normal skeletal muscles with the purpose to deepen the ultrastructural localization of HRG in skeletal muscle fibers. The immunogold analysis evidenced the presence of HRG in the sarcomeres, mainly in the I-band and to a less extent in the A-band, in the heterochromatin of nuclei, and in the sarcoplasmic reticulum. The colocalization of HRG and skeletal muscle AMPD1 was also analyzed. A colabeling of HRG and AMPD1 was evident at sarcomeric, sarcoplasmic reticulum, and nuclear levels. The significance of these interesting and new results is discussed in this article.
Collapse
Affiliation(s)
- Letizia Mattii
- Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa, Italy.,Nutrafood, Centro Interdipartimentale di Ricerca Nutraceutica e Alimentazione per la salute, Pisa, Italy
| | - Francesco Bianchi
- Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa, Italy
| | - Alessandra Falleni
- Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa, Italy
| | - Sabina Frascarelli
- Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Università di Pisa, Pisa, Italy
| | - Matilde Masini
- Dipartimento di Ricerca Traslazionale e delle Nuove Tecnologie in Medicina e Chirurgia, Università di Pisa, Pisa, Italy
| | - Greta Alì
- U.O. Anatomia Patologica III, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | - Grazia Chiellini
- Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Università di Pisa, Pisa, Italy
| | - Antonietta R M Sabbatini
- Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Università di Pisa, Pisa, Italy
| |
Collapse
|
6
|
|
7
|
Mutch NJ. Regulation of Fibrinolysis by Platelets. Platelets 2019. [DOI: 10.1016/b978-0-12-813456-6.00023-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
8
|
In vitro assessment of the synergism between extracts of Cocos nucifera husk and some standard antibiotics. Asian Pac J Trop Biomed 2017. [DOI: 10.1016/j.apjtb.2016.12.022] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
9
|
Chauhan AS, Kumar M, Chaudhary S, Patidar A, Dhiman A, Sheokand N, Malhotra H, Iyengar Raje C, Raje M. Moonlighting glycolytic protein glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH): an evolutionarily conserved plasminogen receptor on mammalian cells. FASEB J 2017; 31:2638-2648. [DOI: 10.1096/fj.201600982r] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2016] [Accepted: 02/21/2017] [Indexed: 01/02/2023]
Affiliation(s)
| | - Manoj Kumar
- Institute of Microbial Technology Chandigarh India
| | | | - Anil Patidar
- Institute of Microbial Technology Chandigarh India
| | | | | | | | | | - Manoj Raje
- Institute of Microbial Technology Chandigarh India
- National Institute of Pharmaceutical Education and Research Sahibzada Ajit Singh Nagar Punjab India
| |
Collapse
|
10
|
Functional Regulation of the Plasma Protein Histidine-Rich Glycoprotein by Zn 2+ in Settings of Tissue Injury. Biomolecules 2017; 7:biom7010022. [PMID: 28257077 PMCID: PMC5372734 DOI: 10.3390/biom7010022] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Revised: 02/15/2017] [Accepted: 02/20/2017] [Indexed: 01/05/2023] Open
Abstract
Divalent metal ions are essential nutrients for all living organisms and are commonly protein-bound where they perform important roles in protein structure and function. This regulatory control from metals is observed in the relatively abundant plasma protein histidine-rich glycoprotein (HRG), which displays preferential binding to the second most abundant transition element in human systems, Zinc (Zn2+). HRG has been proposed to interact with a large number of protein ligands and has been implicated in the regulation of various physiological and pathological processes including the formation of immune complexes, apoptotic/necrotic and pathogen clearance, cell adhesion, antimicrobial activity, angiogenesis, coagulation and fibrinolysis. Interestingly, these processes are often associated with sites of tissue injury or tumour growth, where the concentration and distribution of Zn2+ is known to vary. Changes in Zn2+ levels have been shown to modify HRG function by altering its affinity for certain ligands and/or providing protection against proteolytic disassembly by serine proteases. This review focuses on the molecular interplay between HRG and Zn2+, and how Zn2+ binding modifies HRG-ligand interactions to regulate function in different settings of tissue injury.
Collapse
|
11
|
Yang P, Li ZY, Li HQ. Potential Roles of Protease Inhibitors in Cancer Progression. Asian Pac J Cancer Prev 2016; 16:8047-52. [PMID: 26745037 DOI: 10.7314/apjcp.2015.16.18.8047] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Proteases are important molecules that are involved in many key physiological processes. Protease signaling pathways are strictly controlled, and disorders in protease activity can result in pathological changes such as cardiovascular and inflammatory diseases, cancer and neurological disorders. Many proteases have been associated with increasing tumor metastasis in various human cancers, suggesting important functional roles in the metastatic process because of their ability to degrade the extracellular matrix barrier. Proteases are also capable of cleaving non-extracellular matrix molecules. Inhibitors of proteases to some extent can reduce invasion and metastasis of cancer cells, and slow down cancer progression. In this review, we focus on the role of a few proteases and their inhibitors in tumors as a basis for cancer prognostication and therapy.
Collapse
Affiliation(s)
- Peng Yang
- Institute of Biotechnology, Key Laboratory of Chemical Biology and Molecular Engineering of National Ministry of Education, Shanxi University, Taiyuan, China E-mail :
| | | | | |
Collapse
|
12
|
Lindgren KE, Nordqvist S, Kårehed K, Sundström-Poromaa I, Åkerud H. The effect of a specific histidine-rich glycoprotein polymorphism on male infertility and semen parameters. Reprod Biomed Online 2016; 33:180-8. [DOI: 10.1016/j.rbmo.2016.05.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Revised: 05/07/2016] [Accepted: 05/10/2016] [Indexed: 12/27/2022]
|
13
|
Zenón F, Jorge I, Cruz A, Suárez E, Segarra AC, Vázquez J, Meléndez LM, Serrano H. 18O proteomics reveal increased human apolipoprotein CIII in Hispanic HIV-1+ women with HAART that use cocaine. Proteomics Clin Appl 2015; 10:144-55. [PMID: 26255783 DOI: 10.1002/prca.201400204] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Revised: 05/26/2015] [Accepted: 07/27/2015] [Indexed: 11/09/2022]
Abstract
PURPOSE Drug abuse is a major risk factor in the development and progression of HIV-1. This study defines the alterations in the plasma proteome of HIV-1-infected women that use cocaine. EXPERIMENTAL DESIGN Plasma samples from 12 HIV-seropositive Hispanic women under antiretroviral therapy were selected for this study. Six sample pairs were matched between nondrug users and cocaine users. After IgG and albumin depletion, SDS-PAGE, and in-gel digestion, peptides from nondrug users and cocaine users were labeled with (16) O and (18) O, respectively, and subjected to LC-MS/MS and quantitation using Proteome Discover and QuiXoT softwares and validated by ELISA. RESULTS A total of 1015 proteins were identified at 1% false discovery rates (FDR). Statistical analyses revealed 13 proteins with significant changes between the two groups, cocaine and noncocaine users (p < 0.05). The great majority pertained to protection defense function and the rest pertained to transport, homeostatic, regulation, and binding of ligands. Apolipoprotein CIII was increased in plasma of HIV+ Hispanic women positive for cocaine compared to HIV+ nondrug users (p ≤ 0.05). CONCLUSIONS AND CLINICAL RELEVANCE Increased human apolipoprotein CIII warrants that these patients be carefully monitored to avoid the increased risk of cardiovascular events associated with HIV, HAART, and cocaine use.
Collapse
Affiliation(s)
- Frances Zenón
- Department of Microbiology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
| | - Inmaculada Jorge
- Laboratorio de Proteómica Cardiovascular, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Ailed Cruz
- Department of Biochemistry, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
| | - Erick Suárez
- Department of Biostatistics and Epidemiology, Graduate School of Public Health, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
| | - Annabell C Segarra
- Department of Physiology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
| | - Jesús Vázquez
- Laboratorio de Proteómica Cardiovascular, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Loyda M Meléndez
- Department of Microbiology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
| | - Horacio Serrano
- Department of Internal Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
| |
Collapse
|
14
|
Kassaar O, Schwarz-Linek U, Blindauer CA, Stewart AJ. Plasma free fatty acid levels influence Zn(2+) -dependent histidine-rich glycoprotein-heparin interactions via an allosteric switch on serum albumin. J Thromb Haemost 2015; 13:101-10. [PMID: 25353308 PMCID: PMC4309485 DOI: 10.1111/jth.12771] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Accepted: 10/21/2014] [Indexed: 01/30/2023]
Abstract
BACKGROUND Histidine-rich glycoprotein (HRG) regulates coagulation through its ability to bind and neutralize heparins. HRG associates with Zn(2+) to stimulate HRG-heparin complex formation. Under normal conditions, the majority of plasma Zn(2+) associates with human serum albumin (HSA). However, free fatty acids (FFAs) allosterically disrupt Zn(2+) binding to HSA. Thus, high levels of circulating FFAs, as are associated with diabetes, obesity, and cancer, may increase the proportion of plasma Zn(2+) associated with HRG, contributing to an increased risk of thrombotic disease. OBJECTIVES To characterize Zn(2+) binding by HRG, examine the influence that FFAs have on Zn(2+) binding by HSA, and establish whether FFA-mediated displacement of Zn(2+) from HSA may influence HRG-heparin complex formation. METHODS Zn(2+) binding to HRG and to HSA in the presence of different FFA (myristate) concentrations were examined by isothermal titration calorimetry (ITC) and the formation of HRG-heparin complexes in the presence of different Zn(2+) concentrations by both ITC and ELISA. RESULTS AND CONCLUSIONS We found that HRG possesses 10 Zn(2+) sites (K' = 1.63 × 10(5) ) and that cumulative binding of FFA to HSA perturbed its ability to bind Zn(2+) . Also Zn(2+) binding was shown to increase the affinity with which HRG interacts with unfractionated heparins, but had no effect on its interaction with low molecular weight heparin (~ 6850 Da). [Correction added on 1 December 2014, after first online publication: In the preceding sentence, "6850 kDa" was corrected to "6850 Da".] Speciation modeling of plasma Zn(2+) based on the data obtained suggests that FFA-mediated displacement of Zn(2+) from serum albumin would be likely to contribute to the development of thrombotic complications in individuals with high plasma FFA levels.
Collapse
Affiliation(s)
- O Kassaar
- School of Medicine, University of St AndrewsSt Andrews, UK
| | - U Schwarz-Linek
- Biomedical Sciences Research Complex, University of St AndrewsSt Andrews, UK
| | - C A Blindauer
- Department of Chemistry, University of WarwickCoventry, UK
| | - A J Stewart
- School of Medicine, University of St AndrewsSt Andrews, UK
| |
Collapse
|
15
|
Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance. Cytokine Growth Factor Rev 2014; 26:293-310. [PMID: 25465594 DOI: 10.1016/j.cytogfr.2014.11.007] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Revised: 11/10/2014] [Accepted: 11/11/2014] [Indexed: 11/21/2022]
Abstract
Angiogenesis is implicated in several pathological conditions, including cancer, and in regenerative processes, including the formation of collateral blood vessels after stroke. Physiological angiogenesis is the outcome of a fine balance between the action of angiogenic growth factors (AGFs) and anti-angiogenic molecules, while pathological angiogenesis occurs when this balance is pushed toward AGFs. AGFs interact with multiple endothelial cell (EC) surface receptors inducing cell proliferation, migration and proteases upregulation. On the contrary, free or extracellular matrix-associated molecules inhibit angiogenesis by sequestering AGFs (thus hampering EC stimulation) or by interacting with specific EC receptors inducing apoptosis or decreasing responsiveness to AGFs. Thus, angiogenesis results from an intricate network of interactions among pro- and anti-angiogenic molecules, EC receptors and various modulators. All these interactions represent targets for the development of pro- or anti-angiogenic therapies. These aims call for suitable technologies to study the countless interactions occurring during neovascularization. Surface plasmon resonance (SPR) is a label-free optical technique to study biomolecular interactions in real time. It has become the golden standard technology for interaction analysis in biomedical research, including angiogenesis. From a survey of the literature it emerges that SPR has already contributed substantially to the better understanding of the neovascularization process, laying the basis for the decoding of the angiogenesis "interactome" and the identification of "hub molecules" that may represent preferential targets for an efficacious modulation of angiogenesis. Here, the still unexploited full potential of SPR is enlightened, pointing to improvements in its use for a deeper understanding of the mechanisms of neovascularization and the identification of novel anti-angiogenic drugs.
Collapse
|
16
|
Ranieri-Raggi M, Moir AJG, Raggi A. The role of histidine-proline-rich glycoprotein as zinc chaperone for skeletal muscle AMP deaminase. Biomolecules 2014; 4:474-97. [PMID: 24970226 PMCID: PMC4101493 DOI: 10.3390/biom4020474] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2014] [Revised: 04/08/2014] [Accepted: 04/10/2014] [Indexed: 11/19/2022] Open
Abstract
Metallochaperones function as intracellular shuttles for metal ions. At present, no evidence for the existence of any eukaryotic zinc-chaperone has been provided although metallochaperones could be critical for the physiological functions of Zn2+ metalloenzymes. We propose that the complex formed in skeletal muscle by the Zn2+ metalloenzyme AMP deaminase (AMPD) and the metal binding protein histidine-proline-rich glycoprotein (HPRG) acts in this manner. HPRG is a major plasma protein. Recent investigations have reported that skeletal muscle cells do not synthesize HPRG but instead actively internalize plasma HPRG. X-ray absorption spectroscopy (XAS) performed on fresh preparations of rabbit skeletal muscle AMPD provided evidence for a dinuclear zinc site in the enzyme compatible with a (μ-aqua)(μ-carboxylato)dizinc(II) core with two histidine residues at each metal site. XAS on HPRG isolated from the AMPD complex showed that zinc is bound to the protein in a dinuclear cluster where each Zn2+ ion is coordinated by three histidine and one heavier ligand, likely sulfur from cysteine. We describe the existence in mammalian HPRG of a specific zinc binding site distinct from the His-Pro-rich region. The participation of HPRG in the assembly and maintenance of skeletal muscle AMPD by acting as a zinc chaperone is also demonstrated.
Collapse
Affiliation(s)
- Maria Ranieri-Raggi
- Laboratory of Biochemistry, Department of Pathology, University of Pisa, via Roma 55, Pisa 56126, Italy.
| | - Arthur J G Moir
- Department of Molecular Biology and Biotechnology, Krebs Institute, University of Sheffield, Sheffield S10 2UH, UK.
| | - Antonio Raggi
- Laboratory of Biochemistry, Department of Pathology, University of Pisa, via Roma 55, Pisa 56126, Italy.
| |
Collapse
|
17
|
Kassaar O, McMahon SA, Thompson R, Botting CH, Naismith JH, Stewart AJ. Crystal structure of histidine-rich glycoprotein N2 domain reveals redox activity at an interdomain disulfide bridge: implications for angiogenic regulation. Blood 2014; 123:1948-55. [PMID: 24501222 PMCID: PMC3962167 DOI: 10.1182/blood-2013-11-535963] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2013] [Accepted: 02/02/2014] [Indexed: 11/20/2022] Open
Abstract
Histidine-rich glycoprotein (HRG) is a plasma protein consisting of 6 distinct functional domains and is an important regulator of key cardiovascular processes, including angiogenesis and coagulation. The protein is composed of 2 N-terminal domains (N1 and N2), 2 proline-rich regions (PRR1 and PRR2) that flank a histidine-rich region (HRR), and a C-terminal domain. To date, structural information of HRG has largely come from sequence analysis and spectroscopic studies. It is thought that an HRG fragment containing the HRR, released via plasmin-mediated cleavage, acts as a negative regulator of angiogenesis in vivo. However, its release also requires cleavage of a disulphide bond suggesting that its activity is mediated by a redox process. Here, we present a 1.93 Å resolution crystal structure of the N2 domain of serum-purified rabbit HRG. The structure confirms that the N2 domain, which along with the N1 domain, forms an important molecular interaction site on HRG, possesses a cystatin-like fold composed of a 5-stranded antiparallel β-sheet wrapped around a 5-turn α-helix. A native N-linked glycosylation site was identified at Asn184. Moreover, the structure reveals the presence of an S-glutathionyl adduct at Cys185, which has implications for the redox-mediated release of the antiangiogenic cleavage product from HRG.
Collapse
|
18
|
Patel KK, Poon IKH, Talbo GH, Perugini MA, Taylor NL, Ralph TJ, Hoogenraad NJ, Hulett MD. New method for purifying histidine-rich glycoprotein from human plasma redefines its functional properties. IUBMB Life 2013; 65:550-63. [DOI: 10.1002/iub.1168] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2013] [Accepted: 03/05/2013] [Indexed: 12/12/2022]
|
19
|
New Insights into the Functions of Histidine-Rich Glycoprotein. INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY 2013; 304:467-93. [DOI: 10.1016/b978-0-12-407696-9.00009-9] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
20
|
La Mendola D, Magrì A, Santoro AM, Nicoletti VG, Rizzarelli E. Copper(II) interaction with peptide fragments of histidine–proline-rich glycoprotein: Speciation, stability and binding details. J Inorg Biochem 2012; 111:59-69. [DOI: 10.1016/j.jinorgbio.2012.02.027] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2011] [Revised: 02/17/2012] [Accepted: 02/20/2012] [Indexed: 12/23/2022]
|
21
|
von Zychlinski A, Kleffmann T, Williams MJA, McCormick SP. Proteomics of Lipoprotein(a) identifies a protein complement associated with response to wounding. J Proteomics 2011; 74:2881-91. [PMID: 21802535 DOI: 10.1016/j.jprot.2011.07.008] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2011] [Revised: 07/06/2011] [Accepted: 07/11/2011] [Indexed: 10/18/2022]
Abstract
Lipoprotein(a) [Lp(a)] is a major independent risk factor for cardiovascular disease. Twenty percent of the general population exhibit levels above the risk threshold highlighting the importance for clinical and basic research. Comprehensive proteomics of human Lp(a) will provide significant insights into Lp(a) physiology and pathogenicity. Using liquid chromatography-coupled mass spectrometry, we established a high confidence Lp(a) proteome of 35 proteins from highly purified particles. Protein interaction network analysis and functional clustering revealed proteins assigned to the two major biological processes of lipid metabolism and response to wounding. The latter includes the processes of coagulation, complement activation and inflammatory response. Furthermore, absolute protein quantification of apoB-100, apo(a), apoA1, complement C3 and PON1 gave insights into the compositional stoichiometry of associated proteins per particle. Our proteomics study has identified Lp(a)-associated proteins that support a suggested role of Lp(a) in response to wounding which points to mechanisms of Lp(a) pathogenicity at sites of vascular injury and atherosclerotic lesions. This study has identified a high confidence Lp(a) proteome and provides an important basis for further comparative and quantitative analyses of Lp(a) isolated from greater numbers of plasma samples to investigate the significance of associated proteins and their dynamics for Lp(a) pathogenicity.
Collapse
|
22
|
Vu TT, Stafford AR, Leslie BA, Kim PY, Fredenburgh JC, Weitz JI. Histidine-rich glycoprotein binds fibrin(ogen) with high affinity and competes with thrombin for binding to the gamma'-chain. J Biol Chem 2011; 286:30314-30323. [PMID: 21757718 DOI: 10.1074/jbc.m111.253831] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Histidine-rich glycoprotein (HRG) is an abundant protein that binds fibrinogen and other plasma proteins in a Zn(2+)-dependent fashion but whose function is unclear. HRG has antimicrobial activity, and its incorporation into fibrin clots facilitates bacterial entrapment and killing and promotes inflammation. Although these findings suggest that HRG contributes to innate immunity and inflammation, little is known about the HRG-fibrin(ogen) interaction. By immunoassay, HRG-fibrinogen complexes were detected in Zn(2+)-supplemented human plasma, a finding consistent with a high affinity interaction. Surface plasmon resonance determinations support this concept and show that in the presence of Zn(2+), HRG binds the predominant γ(A)/γ(A)-fibrinogen and the γ-chain elongated isoform, γ(A)/γ'-fibrinogen, with K(d) values of 9 nm. Likewise, (125)I-labeled HRG binds γ(A)/γ(A)- or γ(A)/γ'-fibrin clots with similar K(d) values when Zn(2+) is present. There are multiple HRG binding sites on fibrin(ogen) because HRG binds immobilized fibrinogen fragment D or E and γ'-peptide, an analog of the COOH terminus of the γ'-chain that mediates the high affinity interaction of thrombin with γ(A)/γ'-fibrin. Thrombin competes with HRG for γ'-peptide binding and displaces (125)I-HRG from γ(A)/γ'-fibrin clots and vice versa. Taken together, these data suggest that (a) HRG circulates in complex with fibrinogen and that the complex persists upon fibrin formation, and (b) by competing with thrombin for γ(A)/γ'-fibrin binding, HRG may modulate coagulation. Therefore, the HRG-fibrin interaction may provide a novel link between coagulation, innate immunity, and inflammation.
Collapse
Affiliation(s)
- Trang T Vu
- Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario L8L 2X2, Canada; the Departments of Medical Sciences, McMaster University, Hamilton, Ontario L8L 2X2, Canada
| | - Alan R Stafford
- Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario L8L 2X2, Canada; Medicine, McMaster University, Hamilton, Ontario L8L 2X2, Canada
| | - Beverly A Leslie
- Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario L8L 2X2, Canada; Medicine, McMaster University, Hamilton, Ontario L8L 2X2, Canada
| | - Paul Y Kim
- Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario L8L 2X2, Canada; Medicine, McMaster University, Hamilton, Ontario L8L 2X2, Canada
| | - James C Fredenburgh
- Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario L8L 2X2, Canada; Medicine, McMaster University, Hamilton, Ontario L8L 2X2, Canada
| | - Jeffrey I Weitz
- Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario L8L 2X2, Canada; the Departments of Medical Sciences, McMaster University, Hamilton, Ontario L8L 2X2, Canada; Medicine, McMaster University, Hamilton, Ontario L8L 2X2, Canada.
| |
Collapse
|
23
|
Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation. Blood 2011; 117:4134-41. [DOI: 10.1182/blood-2010-07-290551] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Abstract
Histidine-rich glycoprotein (HRG) circulates in plasma at a concentration of 2μM and binds plasminogen, fibrinogen, and thrombospondin. Despite these interactions, the physiologic role of HRG is unknown. Previous studies have shown that mice and humans deficient in HRG have shortened plasma clotting times. To better understand this phenomenon, we examined the effect of HRG on clotting tests. HRG prolongs the activated partial thromboplastin time in a concentration-dependent fashion but has no effect on tissue factor–induced clotting, localizing its effect to the contact pathway. Plasma immunodepleted of HRG exhibits a shortened activated partial thromboplastin time that is restored to baseline with HRG replenishment. To explore how HRG affects the contact pathway, we examined its binding to factors XII, XIIa, XI, and XIa. HRG binds factor XIIa with high affinity, an interaction that is enhanced in the presence of Zn2+, but does not bind factors XII, XI, or XIa. In addition, HRG inhibits autoactivation of factor XII and factor XIIa–mediated activation of factor XI. These results suggest that, by binding to factor XIIa, HRG modulates the intrinsic pathway of coagulation, particularly in the vicinity of a thrombus where platelet release of HRG and Zn2+ will promote this interaction.
Collapse
|
24
|
Leksa V, Loewe R, Binder B, Schiller HB, Eckerstorfer P, Forster F, Soler-Cardona A, Ondrovičová G, Kutejová E, Steinhuber E, Breuss J, Drach J, Petzelbauer P, Binder BR, Stockinger H. Soluble M6P/IGF2R Released by TACE Controls Angiogenesis via Blocking Plasminogen Activation. Circ Res 2011; 108:676-85. [DOI: 10.1161/circresaha.110.234732] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Rationale:
The urokinase plasminogen activator (uPA) system is among the most crucial pericellular proteolytic systems associated with the processes of angiogenesis. We previously identified an important regulator of the uPA system in the mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R).
Objective:
Here, we wanted to clarify whether and how did the soluble form of M6P/IGF2R (sM6P/IGF2R) contribute to modulation of the uPA system.
Methods and Results:
By using specific inhibitors and RNA interference, we show that the tumor necrosis factor α convertase (TACE, ADAM-17) mediates the release of the ectodomain of M6P/IGF2R from human endothelial cells. We demonstrate further that sM6P/IGF2R binds plasminogen (Plg) and thereby prevents Plg from binding to the cell surface and uPA, ultimately inhibiting in this manner Plg activation. Furthermore, peptide 18-36 derived from the Plg-binding site of M6P/IGF2R mimics sM6P/IGF2R in the inhibition of Plg activation and blocks cancer cell invasion in vitro, endothelial cell invasion in vivo, and tumor growth in vivo.
Conclusions:
The interaction of sM6P/IGF2R with Plg may be an important regulatory mechanism to inhibit migration of cells using the uPA/uPAR system.
Collapse
Affiliation(s)
- Vladimir Leksa
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Robert Loewe
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Brigitte Binder
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Herbert B. Schiller
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Paul Eckerstorfer
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Florian Forster
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Ana Soler-Cardona
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Gabriela Ondrovičová
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Eva Kutejová
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Eva Steinhuber
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Johannes Breuss
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Johannes Drach
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Peter Petzelbauer
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Bernd R. Binder
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Hannes Stockinger
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| |
Collapse
|
25
|
Schaller J, Gerber SS. The plasmin-antiplasmin system: structural and functional aspects. Cell Mol Life Sci 2011; 68:785-801. [PMID: 21136135 PMCID: PMC11115092 DOI: 10.1007/s00018-010-0566-5] [Citation(s) in RCA: 87] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2010] [Revised: 09/03/2010] [Accepted: 10/12/2010] [Indexed: 10/18/2022]
Abstract
The plasmin-antiplasmin system plays a key role in blood coagulation and fibrinolysis. Plasmin and α(2)-antiplasmin are primarily responsible for a controlled and regulated dissolution of the fibrin polymers into soluble fragments. However, besides plasmin(ogen) and α(2)-antiplasmin the system contains a series of specific activators and inhibitors. The main physiological activators of plasminogen are tissue-type plasminogen activator, which is mainly involved in the dissolution of the fibrin polymers by plasmin, and urokinase-type plasminogen activator, which is primarily responsible for the generation of plasmin activity in the intercellular space. Both activators are multidomain serine proteases. Besides the main physiological inhibitor α(2)-antiplasmin, the plasmin-antiplasmin system is also regulated by the general protease inhibitor α(2)-macroglobulin, a member of the protease inhibitor I39 family. The activity of the plasminogen activators is primarily regulated by the plasminogen activator inhibitors 1 and 2, members of the serine protease inhibitor superfamily.
Collapse
Affiliation(s)
- Johann Schaller
- Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, Bern, Switzerland.
| | | |
Collapse
|
26
|
Abstract
AbstractHistidine-rich glycoprotein (HRG), also known as histidine-proline-rich glyco-protein, is an abundant and well-characterized protein of vertebrate plasma. HRG has a multidomain structure that allows the molecule to interact with many ligands, including heparin, phospholipids, plasminogen, fibrinogen, immunoglobulin G, C1q, heme, and Zn2+. The ability of HRG to interact with various ligands simultaneously has suggested that HRG can function as an adaptor molecule and regulate numerous important biologic processes, such as immune complex/necrotic cell/pathogen clearance, cell adhesion, angiogenesis, coagulation, and fibrinolysis. The present review covers the proposed multifunctional roles of HRG with a focus on recent findings that have led to its emergence as a key regulator of immunity and vascular biology. Also included is a discussion of the striking functional similarities between HRG and other important multifunctional proteins found in plasma, such as C-reactive protein, C1q, β2 glycoprotein I, and thrombospondin-1.
Collapse
|
27
|
Jancsó A, Kolozsi A, Gyurcsik B, Nagy NV, Gajda T. Probing the Cu2+ and Zn2+ binding affinity of histidine-rich glycoprotein. J Inorg Biochem 2009; 103:1634-43. [DOI: 10.1016/j.jinorgbio.2009.09.002] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2009] [Revised: 09/01/2009] [Accepted: 09/02/2009] [Indexed: 10/20/2022]
|
28
|
Regulation of histidine-rich glycoprotein (HRG) function via plasmin-mediated proteolytic cleavage. Biochem J 2009; 424:27-37. [DOI: 10.1042/bj20090794] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The plasminogen/plasmin system is involved in a variety of normal physiological and pathological processes, including tissue remodelling, angiogenesis and tumour metastasis. Plasminogen activators and receptors for plasminogen/plasminogen activators are essential for the processing of plasminogen to form the active serine protease plasmin. Plasmin can in turn positively or negatively regulate further plasminogen activation via plasminmediated cleavage of receptors and activators. HRG (histidine-rich glycoprotein), a relatively abundant (approx. 100–150 μg/ml) plasma glycoprotein, has a multi-domain structure that can interact with many ligands, including Zn2+, heparin, HS (heparan sulfate) and plasminogen. HRG has been shown to function as an adaptor molecule to tether plasminogen to GAG (glycosaminoglycan)-bearing surfaces and to regulate plasminogen activation via various mechanisms. As HRG itself is sensitive to plasmin cleavage, the present study examines in detail the cleavage of human HRG by plasmin and the effect of this cleavage on various functions of HRG. HRG fragments, generated by plasmin cleavage, are held together by disulfide linkages and are not released from the molecule under non-reducing conditions. Plasmin-mediated cleavage partially inhibited HRG binding to cell surface HS, but enhanced HRG binding to necrotic cells and to plasminogen. However, both intact and plasmin-cleaved HRG enhanced the binding of plasminogen to heparin-coated surfaces to a similar extent. Furthermore, the presence of heparin, Zn2+ or acidic pH was found to protect HRG from plasmin cleavage. Thus proteolytic cleavage of HRG by plasmin may provide a feedback mechanism to regulate the effects of HRG on the plasminogen/plasmin system and other functions of HRG.
Collapse
|
29
|
Plasma fatty acid levels may regulate the Zn(2+)-dependent activities of histidine-rich glycoprotein. Biochimie 2009; 91:1518-22. [PMID: 19679159 DOI: 10.1016/j.biochi.2009.08.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2009] [Accepted: 08/03/2009] [Indexed: 11/23/2022]
Abstract
Histidine-rich glycoprotein (HRG) is a plasma adaptor protein involved in the formation of protein complexes that regulate a number of biological processes in the blood, most notably coagulation and the immune system. Elevated levels of HRG are clinically linked to thrombotic disorders such as blood vessel occlusion. A large body of evidence suggests that Zn(2+) ions stimulate HRG-complex formation; however, under normal conditions the vast majority of Zn(2+) in the blood is bound to human serum albumin (HSA). We have previously demonstrated that high levels of fatty acid act as an allosteric switch which disrupts the major Zn(2+)-binding site on HSA. Transient or sustained elevation of plasma fatty acid levels may therefore increase the proportion of plasma Zn(2+) associated with HRG. We speculate that this mechanism may potentiate an increased risk of thrombosis in individuals with elevated fatty acid levels such as those associated with cancer, obesity and diabetes.
Collapse
|
30
|
Tubek S, Grzanka P, Tubek I. Role of zinc in hemostasis: a review. Biol Trace Elem Res 2008; 121:1-8. [PMID: 17968515 DOI: 10.1007/s12011-007-8038-y] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2007] [Accepted: 10/01/2007] [Indexed: 10/22/2022]
Abstract
Zinc is a multi-functional element that is found in almost 300 enzymes where it performs catalytic, co-catalytic, and/or structural functions. In 1982, Gordon et al. (Am J Clin Ntr 35:849-857, 1982) found that a low zinc diet caused poor platelet aggregation and increased bleeding tendency in adult males. This fact drew interest to the role of zinc in blood clotting. It has been shown that hyperzincemia predisposes to increased coagulability, and hypozincemia to poor platelet aggregation and increased bleeding time. The blood clotting disturbances can be regressed by appropriate zinc intake management. Considering the importance of zinc as an essential element, its participation in regulation of the equilibrium between pro- and anti-thrombotic factors originating in platelets and endothelium prompted further investigations.
Collapse
Affiliation(s)
- Sławomir Tubek
- Faculty of Physical Education and Physiotherapy, Institute of Technology, Opole, Prószkowska Street 76, 45-758, Opole, Poland.
| | | | | |
Collapse
|
31
|
Ellyard JI, Simson L, Bezos A, Johnston K, Freeman C, Parish CR. Eotaxin selectively binds heparin. An interaction that protects eotaxin from proteolysis and potentiates chemotactic activity in vivo. J Biol Chem 2007; 282:15238-47. [PMID: 17384413 DOI: 10.1074/jbc.m608046200] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
An important feature of chemokines is their ability to bind to the glycosaminoglycan (GAG) side chains of proteoglycans, predominately heparin and heparan sulfate. To date, all chemokines tested bind to immobilized heparin in vitro, as well as cell surface heparan sulfate in vitro and in vivo. These interactions play an important role in modulating the action of chemokines by facilitating the formation of stable chemokine gradients within the vascular endothelium and directing leukocyte migration, by protecting chemokines from proteolysis, by inducing chemokine oligomerization, and by facilitating transcytosis. Despite the importance of eotaxin in eosinophil differentiation and recruitment being well established, little is known about the interaction between eotaxin and GAGs and the functional consequences of such an interaction. Here we report that eotaxin binds selectively to immobilized heparin with high affinity (K(d) = 1.23 x 10(-8) M), but not to heparan sulfate or a range of other GAGs. The interaction of eotaxin with heparin does not promote eotaxin oligomerization but protects eotaxin from proteolysis directly by plasmin and indirectly by cathepsin G and elastase. In vivo, co-administration of eotaxin and heparin is able to significantly enhance eotaxin-mediated eosinophil recruitment in a mouse air-pouch model. Furthermore, when heparin is co-administered with eotaxin at a concentration that does not normally result in eosinophil infiltration, eosinophil recruitment occurs. In contrast, heparin does not enhance eotaxin-mediated eosinophil chemotaxis in vitro, suggesting protease protection or haptotactic gradient formation as the mechanism by which heparin enhances eotaxin action in vivo. These results suggest a role for mast cell-derived heparin in the recruitment of eosinophils, reinforcing Th2 polarization of inflammatory responses.
Collapse
MESH Headings
- Animals
- Anticoagulants/chemistry
- Anticoagulants/metabolism
- Anticoagulants/pharmacology
- Cathepsin G
- Cathepsins/metabolism
- Chemokine CCL11
- Chemokines, CC/chemistry
- Chemokines, CC/metabolism
- Chemokines, CC/pharmacology
- Chemotaxis, Leukocyte/drug effects
- Endothelium, Vascular/metabolism
- Endothelium, Vascular/pathology
- Eosinophils/metabolism
- Eosinophils/pathology
- Fibrinolysin/metabolism
- Heparin/chemistry
- Heparin/metabolism
- Heparin/pharmacology
- Heparitin Sulfate/chemistry
- Heparitin Sulfate/metabolism
- Heparitin Sulfate/pharmacology
- Inflammation/metabolism
- Inflammation/pathology
- Male
- Mast Cells/metabolism
- Mast Cells/pathology
- Mice
- Mice, Inbred BALB C
- Mice, Transgenic
- Models, Biological
- Protein Binding/drug effects
- Protein Processing, Post-Translational/drug effects
- Serine Endopeptidases/metabolism
- Th2 Cells/metabolism
- Th2 Cells/pathology
Collapse
Affiliation(s)
- Julia I Ellyard
- Cancer and Vascular Biology Group, Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Building 54, Garran Road, Acton, Australian Capital Territory 0200, Australia
| | | | | | | | | | | |
Collapse
|
32
|
Vanwildemeersch M, Olsson AK, Gottfridsson E, Claesson-Welsh L, Lindahl U, Spillmann D. The anti-angiogenic His/Pro-rich fragment of histidine-rich glycoprotein binds to endothelial cell heparan sulfate in a Zn2+-dependent manner. J Biol Chem 2006; 281:10298-304. [PMID: 16436387 DOI: 10.1074/jbc.m508483200] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The plasma protein histidine-rich glycoprotein (HRGP), which has been identified as an angiogenesis inhibitor, binds to heparan sulfate (HS) in a Zn(2+)-dependent manner. We wished to test whether this interaction is mechanistically important in mediation of the anti-angiogenic effect of HRGP. Inhibition of angiogenesis by HRGP is exerted through its central His/Pro-rich domain, which is proteolytically released. A 35-amino-acid residue synthetic peptide, HRGP330, derived from the His/Pro-rich domain retains the inhibitory effect on blood vessel formation in vitro and in vivo, an effect dependent on the presence of Zn(2+). We now show that HRGP330 binds heparin/HS with the same capacity as full-length HRGP, and the binding is Zn(2+)-dependent. Peptides derived from the His/Pro-rich domain of HRGP downstream of HRGP330 fail to inhibit endothelial cell migration and display a significantly reduced heparin-binding capacity. An even shorter peptide, HRGP335, covering a 26-amino-acid sequence within HRGP330 retains full heparin/HS-binding capacity. Characterization of the HS interaction shows that there is a tissue-specific HS pattern recognized by HRGP335 and that the minimal length of heparin/HS required for binding to HRGP335 is an 8-mer oligosaccharide. Saturation of the HS binding sites in HRGP330 by pre-incubation with heparin abrogates the HRGP330-induced rearrangement of endothelial cell focal adhesions, suggesting that interaction with cell surface HS is needed for HRGP330 to exert its anti-angiogenic effect.
Collapse
Affiliation(s)
- Maarten Vanwildemeersch
- Department of Medical Biochemistry and Microbiology, Uppsala University, SE-75123 Uppsala, Sweden
| | | | | | | | | | | |
Collapse
|
33
|
Jones AL, Poon IKH, Hulett MD, Parish CR. Histidine-rich Glycoprotein Specifically Binds to Necrotic Cells via Its Amino-terminal Domain and Facilitates Necrotic Cell Phagocytosis. J Biol Chem 2005; 280:35733-41. [PMID: 16107330 DOI: 10.1074/jbc.m504384200] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Cells that become necrotic or apoptotic through tissue damage or during normal cellular turnover are usually rapidly cleared from the circulation and tissues by phagocytic cells. A number of soluble proteins have been identified that facilitate the phagocytosis of apoptotic cells, but few proteins have been defined that selectively opsonize necrotic cells. Previous studies have shown that histidine-rich glycoprotein (HRG), an abundant (approximately 100 microg/ml) 75-kDa plasma glycoprotein, binds to cell surface heparan sulfate on viable cells and cross-links other ligands, such as plasminogen, to the cell surface. In this study we have demonstrated that HRG also binds very strongly, in a heparan sulfate-independent manner, to cytoplasmic ligand(s) exposed in necrotic cells. This interaction is mediated by the amino-terminal domain of HRG and results in enhanced phagocytosis of the necrotic cells by a monocytic cell line. In contrast, it was found that HRG binds poorly to and does not opsonize early stage apoptotic cells. Thus, HRG has the unique property of selectively recognizing necrotic cells and may play an important physiological role in vivo by facilitating the uptake and clearance of necrotic, but not apoptotic, cells by phagocytes.
Collapse
Affiliation(s)
- Allison L Jones
- Cancer and Vascular Biology Group, Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, 0200, Australia
| | | | | | | |
Collapse
|
34
|
Abstract
Cystatins form a large superfamily of proteins with diverse biologic activities. All members of the cystatin superfamily share the presence of one, two or three cystatin domains. Cystatins were initially believed to act mainly as inhibitors of lysosomal cysteine proteases. In recent years, however, there has been increased awareness of additional or alternate biologic functions for these proteins. In this review, the authors will discuss the most recent findings and hypotheses that suggest that some members of the cystatin superfamily may play important roles during tumor progression. Special emphasis is given to their potential role as novel anti-angiogenic agents.
Collapse
Affiliation(s)
- Daniel Keppler
- Louisiana State University Health Sciences Center, Department of Cellular Biology & Anatomy and Feist-Weiller Cancer Center, School of Medicine, Shreveport, LA 71130, USA.
| | | |
Collapse
|
35
|
Tsuchida-Straeten N, Ensslen S, Schäfer C, Wöltje M, Denecke B, Moser M, Gräber S, Wakabayashi S, Koide T, Jahnen-Dechent W. Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J Thromb Haemost 2005; 3:865-72. [PMID: 15869579 DOI: 10.1111/j.1538-7836.2005.01238.x] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Histidine-rich glycoprotein (HRG) is a serum protein belonging to the cystatin superfamily. HRG may play a regulatory role in hemostasis and innate immunity. However, this role is uncertain because of a lack of rigorous testing in an animal model. We generated mice lacking the translation start point of exon 1 of the Hrg gene, effectively resulting in a null mutation (Hrg-/-). The mice were viable and fertile but had no HRG in their blood. Antithrombin activity in the plasma of Hrg-/- mice was higher than in the plasma of heterozygous Hrg+/- or wild-type Hrg+/+ mice. The prothrombin time was shorter in Hrg-/- mice than in Hrg+/- and Hrg+/+ mice. Bleeding time after tail tip amputation in Hrg-/- mice was shorter than in Hrg+/+ mice. The spontaneous fibrinolytic activity in clotted blood of Hrg-/- mice was higher than in Hrg+/+ mice. These findings suggest that HRG plays a role as both an anticoagulant and an antifibrinolytic modifier, and may regulate platelet function in vivo.
Collapse
Affiliation(s)
- N Tsuchida-Straeten
- IZKF BIOMAT, University Hospital, RWTH Aachen, Pauwelsstrasse 30, D-52074, Aachen, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Borza DB. Life without histidine-rich glycoprotein: modulation of the hemostatic balance revisited. J Thromb Haemost 2005; 3:863-4. [PMID: 15869578 DOI: 10.1111/j.1538-7836.2005.01332.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- D-B Borza
- Department of Medicine, Division of Nephrology and Hypertension, Vanderbilt University School of Medicine, Nashville, TN 37232-2372, USA.
| |
Collapse
|
37
|
Jones AL, Hulett MD, Parish CR. Histidine‐rich glycoprotein: A novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. Immunol Cell Biol 2005; 83:106-18. [PMID: 15748207 DOI: 10.1111/j.1440-1711.2005.01320.x] [Citation(s) in RCA: 234] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Histidine-rich glycoprotein (HRG) is an abundant plasma glycoprotein that has a multidomain structure, interacts with many ligands, and has been shown to regulate a number of important biological processes. HRG ligands include Zn(2+) and haem, tropomyosin, heparin and heparan sulphate, plasminogen, plasmin, fibrinogen, thrombospondin, IgG, FcgammaR and complement. In many cases, the histidine-rich region of the molecule enhances ligand binding following interaction with Zn(2+) or exposure to low pH, conditions associated with sites of tissue injury or tumour growth. The multidomain nature of HRG indicates that it can act as an extracellular adaptor protein, bringing together disparate ligands, particularly on cell surfaces. HRG binds to most cells primarily via heparan sulphate proteoglycans, binding which is also potentiated by elevated free Zn(2+) levels and low pH. Recent reports have shown that HRG can modulate angiogenesis and additional studies have shown that it may regulate other physiological processes such as cell adhesion and migration, fibrinolysis and coagulation, complement activation, immune complex clearance and phagocytosis of apoptotic cells. This review outlines the molecular, structural, biological and clinical properties of HRG as well as describing the role of HRG in various physiological processes.
Collapse
Affiliation(s)
- Allison L Jones
- Cancer and Vascular Biology Group, Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | | | | |
Collapse
|
38
|
Abstract
The year 2004 represents a milestone for the biosensor research community: in this year, over 1000 articles were published describing experiments performed using commercially available systems. The 1038 papers we found represent an approximately 10% increase over the past year and demonstrate that the implementation of biosensors continues to expand at a healthy pace. We evaluated the data presented in each paper and compiled a 'top 10' list. These 10 articles, which we recommend every biosensor user reads, describe well-performed kinetic, equilibrium and qualitative/screening studies, provide comparisons between binding parameters obtained from different biosensor users, as well as from biosensor- and solution-based interaction analyses, and summarize the cutting-edge applications of the technology. We also re-iterate some of the experimental pitfalls that lead to sub-optimal data and over-interpreted results. We are hopeful that the biosensor community, by applying the hints we outline, will obtain data on a par with that presented in the 10 spotlighted articles. This will ensure that the scientific community at large can be confident in the data we report from optical biosensors.
Collapse
Affiliation(s)
- Rebecca L Rich
- Center for Biomolecular Interaction Analysis, University of Utah, Salt Lake City, UT 84132, USA
| | | |
Collapse
|